The Effects on Growth and Tolerance of an Infant Formula Fed to Term Infants
1 other identifier
interventional
348
1 country
22
Brief Summary
This clinical trial will evaluate an investigational infant formula with a probiotic to determine if it provides normal growth and if it is well tolerated by term infants compared to a marketed routine infant formula.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jul 2013
Shorter than P25 for not_applicable
22 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2013
CompletedFirst Submitted
Initial submission to the registry
July 3, 2013
CompletedFirst Posted
Study publicly available on registry
July 12, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2014
CompletedSeptember 25, 2015
September 1, 2015
8 months
July 3, 2013
September 24, 2015
Conditions
Outcome Measures
Primary Outcomes (1)
Body weight measured at each study visit
3.5 months
Secondary Outcomes (7)
Recall of infant formula intake at each study visit
3.5 months
Body length measured at each study visit
3.5 months
Recall of stool consistency measured at each study visit
3.5 months
Medically-confirmed adverse events collected throughout the study period
3.5 months
Parental Study Product Assessment Questionnaire completed at Study Visit 2
once
- +2 more secondary outcomes
Study Arms (2)
Marketed routine infant formula
ACTIVE COMPARATORInfant formula containing a probiotic source
EXPERIMENTALInterventions
Eligibility Criteria
You may qualify if:
- Singleton, 12-16 days of age at randomization
- Term infant with birth weight of a minimum of 2500 grams
- Solely formula fed
- Signed Informed Consent and Protected Health Information
You may not qualify if:
- History of underlying metabolic or chronic disease or immunocompromised
- Feeding difficulties or formula intolerance
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (22)
Birmingham Pediatric Associates
Birmingham, Alabama, 35205, United States
Greenvale Pediatrics Hoover
Birmingham, Alabama, 35244, United States
Southeastern Pediatric Associates
Dothan, Alabama, 36305, United States
Pediatrics East - Alabama Clinical Therapeutics
Pinson, Alabama, 35126, United States
The Children's Clinic of Jonesboro, P.A.
Jonesboro, Arkansas, 72401, United States
Arkkansas Pediatric Clinic
Little Rock, Arkansas, 72205, United States
Norwich Pediatric Group, P.C.
Norwich, Connecticut, 06360, United States
Children's Research, LLC
Altamonte Springs, Florida, 32701, United States
Children's Medical Associations
Plantation, Florida, 33324, United States
Deaconess Clinical Research
Evansville, Indiana, 47713, United States
Owensboro Pediatrics
Owensboro, Kentucky, 42303, United States
Woburn Pediatic Associates
Woburn, Massachusetts, 01801, United States
Cary Pediatric Center, P.A.
Cary, North Carolina, 27518, United States
Capital Pediatrics & Adolescent Center
Raleigh, North Carolina, 27609, United States
Pediatric Associates of Mt. Carmel, Inc
Cincinnati, Ohio, 45245, United States
Pediatric Associates of Fairfield, Inc.
Fairfield, Ohio, 45014, United States
Parma Pediatrics, Inc
Parma, Ohio, 44129, United States
UHMP Comprehensive Pediatrics
Westlake, Ohio, 44145, United States
The Jackson Clinic - North Jackson
Jackson, Tennessee, 38305, United States
Holston Medical Group
Kingsport, Tennessee, 37660, United States
Austin Diagnostic Clinic
Austin, Texas, 78749, United States
DCOL Center for Clinical Research
Longview, Texas, 75605, United States
Related Publications (1)
Berseth CL, Yeiser M, Harris CL, Kinnaman JN, Lappin V, Wampler JL, Zhuang W, Vanderhoof J. Infant formula with added Lacticaseibacillus rhamnosus GG supported adequate growth and was well tolerated in healthy term infants: a randomized controlled trial. Front Pediatr. 2024 Oct 23;12:1456607. doi: 10.3389/fped.2024.1456607. eCollection 2024.
PMID: 39507493DERIVED
Study Officials
- STUDY DIRECTOR
Carol Lynn Berseth, M.D.
Mead Johnson Nutrition
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 3, 2013
First Posted
July 12, 2013
Study Start
July 1, 2013
Primary Completion
March 1, 2014
Study Completion
April 1, 2014
Last Updated
September 25, 2015
Record last verified: 2015-09